The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Past, present and future of hemophilia: a narrative review
Open accessAbstract
Over the past forty years the availability of coagulation factor replacement therapy has greatly contributed to the improved care of people with hemophilia. Following the blood-borne viral infections in the late 1970s and early 1980, caused by coagulation factor concentrates manufactured using non-virally inactivated pooled plasma, the need for safer treatment became crucial to the hemophilia community. The introduction of virus inactivated plasma-derived coagulation factors and then of recombinant products has revolutionized the care of these people. These therapeutic weapons have improved their quality of life and that of their families and permitted home treatment, i.e., factor replacement therapy at regular intervals in order to prevent both bleeding and the resultant joint damage (i.e. primary prophylaxis). Accordingly, a near normal lifestyle and life-expectancy have been achieved. The main current problem in hemophilia is the onset of alloantibodies inactivating the infused coagulation factor, even though immune tolerance regimens based on long-term daily injections of large dosages of coagulation factors are able to eradicate inhibitors in approximately two-thirds of affected patients. In addition availability of products that bypass the intrinsic coagulation defects have dramatically improved the management of this complication. The major challenges of current treatment regimens, such the short half life of hemophilia therapeutics with need for frequent intravenous injections, encourage the current efforts to produce coagulation factors with more prolonged bioavailability. Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“While primary prophylaxis remains the gold standard for preserving joint function in babies with severe hemophilia [48], there is actually a debate regarding the effects on joint status of secondary prophylaxis compared with on demand therapy in older children, adolescents and adults [49].”
BackgroundPossible transmission of variant Creutzfeldt-Jakob disease by blood transfusion
Llewelyn, C., Hewitt, P., Knight, R., Amar, K., Cousens, S., Mackenzie, J., & Will, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15486-x · Cited by 1,128
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Bolton-Maggs, P. H., & Pasi, K. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13405-8 · Cited by 763
Gouw, S. C., van der Bom, J. G., & Marijke van den Berg, H. (2007) · Blood · doi:10.1182/blood-2006-11-056291 · Cited by 495
Astermark, J., Donfield, S. M., DiMichele, D. M., Gringeri, A., Gilbert, S. A., Waters, J., Berntorp, E., & for the FENOC Study Group (2007) · Blood · doi:10.1182/blood-2006-04-017988 · Cited by 473
Biggs, R., Douglas, A. S., Macfarlane, R. G., Dacie, J. V., Pitney, W. R., Merskey, C., & O'Brien, J. R. (1952) · BMJ · doi:10.1136/bmj.2.4799.1378 · Cited by 427
Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A
Roth, D. A., Tawa, N. E., O'Brien, J. M., Treco, D. A., & Selden, R. F. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442301 · Cited by 364
Cited by
Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158
Metadata
- Authors
- Franchini, M., & Mannucci, P.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2012
- Volume
- 7
- Issue
- 1
- Pages
- 24
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2112961788
- Cited by
- 281
- References
- 57
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Past, present and future of hemophilia: a narrative review. https://app.cochat.ai/papers/10.1186/1750-1172-7-24
- The paper
- Franchini, M., & Mannucci, P. (2012). Past, present and future of hemophilia: a narrative review. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-7-24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.